After a volatile prior period, 2025 marked a recovery for mid-cap biotech. Clinical execution improved, financing conditions stabilised, and M&A activity supported sector sentiment. BB Biotech expects innovation-driven deal activity to remain supportive. The portfolio saw selective additions and disciplined capital rotation. A dividend of CHF 2.25 per share will be proposed together with a share buyback programme of up to 10% over three years.
LÄS MER
